Drug news
Sycrest(Lundbeck) is launched for Bipolar Disorder in UK
Sycrest (asenapine)from Lundbeck is launched in the UK for treatment of moderate to severe manic episodes associated with Bipolar Disorder in adults. EU approval was given in 2010. Sycrest is licensed by Lundbeck from Merck Inc. which markets the drug in the USA as Saphris for Schizophrenia and Bipolar Disorder. The advantages of the new antipsychotic are less weight gain than with traditional antipsychotics and rapid efficacy which starts as early as day two.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins